UK
New lab data from British American Tobacco (BAT) has revealed that vapor from the iFuse, BAT’s new hybrid tobacco heating product (THP), and two standard THPs produced little or no effect on human cells in biological testing.
Dr. James Murphy, head of reduced risk substantiation at BAT, said, “Our results suggest that these standard THPs and our novel hybrid product have the potential to reduce smoking-related disease risks when compared with cigarette smoking. However, further pre-clinical and clinical research is required to substantiate conclusive risk reduction of these products.”
A series of lab-based biological studies were used to assess and compare the toxicological and biological effects of exposure to vapor from the hybrid iFuse, two different standard THPs, and smoke from a 3R4F reference cigarette. The tests looked at the general health of the cells, mutations and damage to DNA, tumor promotion, oxidative stress, and wound repair, all of which are involved in the development of many smoking-related diseases.
Results show that cigarette smoke tested positive on all counts, whereas the hybrid and standard THPs did not cause mutations or damage to DNA, and showed considerably reduced responses in the other tests. Overall, the hybrid tobacco heating product had the least effect, showing little to no biological activity in any of the assays in which it was tested.
The iFuse works like an e-cigarette with a pod containing tobacco. An e-liquid is heated to produce an aerosol that passes through the tobacco pod. The aerosol cools from around 35ºC to 32ºC as it passes over the tobacco, heating up the pod sufficiently to extract flavor without any direct heating of the tobacco. The device heats tobacco to around 34°C, which is different from standard THPs that heats tobacco to around 240-350°C.
These temperatures are not high enough to burn the tobacco and the resulting vapors contain far fewer and lower levels of toxicants than cigarette smoke, which can reach temperatures of over 900°C during puffing.